Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 3/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23918942 | 0.77 | NR1I2 (0.36) | NR1I2LMNAESR1 | |
| SCHEMBL23918943 | 0.73 | NR1I2 (0.35) | NR1I2LMNAESR1DNM1OPRM1 | |
| SCHEMBL23918554 | 0.70 | NR1I2 (0.43) | NR1I2LMNAESR1 | |
| SCHEMBL23918692 | 0.68 | NR1I2 (0.35) | NR1I2GPR84 | |
| SCHEMBL23918689 | 0.67 | NR1I2 (0.36) | NR1I2LMNADNM1 | |
| SCHEMBL8812385 | 0.67 | ESR1 (0.44) | ESR1TSHRTHRBGPR84 | |
| SCHEMBL21423075 | 0.65 | MEN1 (0.41) | NR1I2 | |
| SCHEMBL21286983 | 0.64 | HTT (0.43) | TTRESR1THRB | |
| SCHEMBL26882687 | 0.63 | PTGS2 (0.57) | LMNAESR1GPR84 | |
| SCHEMBL26882878 | 0.63 | PTGS2 (0.57) | LMNAESR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | NR1I2 602/4885TTR 2683/4885LMNA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.